Document is current

Article History

Received: 16 December 2025

Accepted: 16 March 2026

First Online: 27 March 2026

Declarations

:

: MDS methylation data were obtained from Tobiasson et al., Oncotarget 2017; 8 [17]:28812–28825, which conducted research in accordance with the Declaration of Helsinki, approved by the Ethical committee at Karolinska Institutet, Sweden (Dnr 2010/427 − 31/1). Primary AML data were obtained from Champions Oncology, which conducted research under the approval of the University of Pennsylvania’s Institutional Review Board (IRB protocol 703185). This study did not involve direct recruitment or enrollment of human participants. All human-derived data were obtained from previously published studies or commercially available de-identified sources. Informed consent was obtained from all participants by the original investigators in each source study: Tobiasson et al. (Oncotarget, 2017) for MDS data, and Champions Oncology under IRB protocol 703185 for primary AML data. Publicly available AML datasets accessed via cBioPortal contain de-identified data for which informed consent was obtained from all participants by the original study investigators.

: This study does not contain identifiable individual patient data. All data were obtained from previously published or commercially available de-identified sources.

: F.G., L.B., M.S., A.D.M., M.A. are employees of Sprint Bioscience AB. A.H and J.W. are employees of NeoTargets AB. A.D.M., M.A. and A.H. are shareholders in Sprint Bioscience AB. M.T. declares no conflict of interest.